Standigm Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
May 2042
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
No maintenance fee falls due on this company's record before Nov 21, 2027.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 3 of 3
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 12,417,849 | Method for Identifying Association Between Disease-Related Factors from Document Data, and System Constructed Using Same In force · High confidence | In force | High confidence | |
| US 12,594,279 | COMPOSITION FOR PREVENTING OR TREATING TNF-alpha-RELATED DISEASE, COMPRISING HYDROFLUMETHIAZIDE AS ACTIVE INGREDIENT In force · High confidence | In force | High confidence | |
| US 12,521,398 | Composition for Treating Synucleinopathies In force · High confidence | In force | High confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending · 4 abandoned · 4 no status recorded
Showing 1 to 9 of 9, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.
| Application | Title | Filed | Status |
|---|---|---|---|
| 19/100,913 | Composition for Prevention, Alleviation, or Treatment of Neurodegenerative Diseases, Comprising Fexofenadine | Aug 4, 2023 | Pending |
| 18/274,416 | Jan 27, 2022 | No status recorded | |
| 18/007,407 | Novel Therapeutic Uses of Compounds for Enhancing Mitochondrial Function and Treating Mitochondrial Diseases | Jul 28, 2021 | Abandoned |
| 18/262,721 | Novel Therapeutic Method for Enhancing Mitochondrial Function, Treating Mitochondrial Diseases Thereby, and Compounds Used Therein | Jul 16, 2021 | Abandoned |
| 17/297,352 | Method of Predicting Disease, Gene or Protein Related to Queried Entity and Prediction System Built by Using the Same | Feb 1, 2021 | Abandoned |
| 17/757,699 | Dec 16, 2020 | Abandoned | |
| 17/770,555 | Oct 20, 2020 | No status recorded | |
| 17/618,354 | Jun 16, 2020 | No status recorded | |
| 15/458,093 | Mar 14, 2017 | No status recorded |